Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States.
| Revenue (Most Recent Fiscal Year) | $47.07M |
| Net Income (Most Recent Fiscal Year) | $-223.86M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 67.58 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.83 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -616.03% |
| Net Margin (Trailing 12 Months) | -616.03% |
| Return on Equity (Trailing 12 Months) | -31.60% |
| Return on Assets (Trailing 12 Months) | -27.12% |
| Current Ratio (Most Recent Fiscal Quarter) | 8.32 |
| Quick Ratio (Most Recent Fiscal Quarter) | 8.32 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $13.59 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.95 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.98 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.47 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 71.50M |
| Free Float | 60.05M |
| Market Capitalization | $3.02B |
| Average Volume (Last 20 Days) | 0.63M |
| Beta (Past 60 Months) | 2.18 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 16.01% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |